Navigation Links
INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray
Date:3/8/2010

Dr. Richard Rauck, a principal investigator in the Phase III study observed, "The sublingual spray demonstrated very rapid, effective pain relief. Patients began to experience meaningful pain relief within five minutes. This observation was supported by the clinical research findings.  To date, no other transmucosal Fentanyl product has produced pain relief this quickly. This early finding is supported with continued pain relief at all subsequent time intervals.  An easy-to-use oral spray that can produce effective, potent and very rapid pain relief will be a tremendous advantage for our patients who experience moderate to severe cancer breakthrough pain."

Michael Babich, President and COO of INSYS, adds, "We are delighted to announce today's results as it validates our thesis that a delivery system that can be administered in seconds will be a benefit to patients suffering from this indication.  More importantly, the results seen at five minutes will benefit patients and doctors who may struggle to find a product that can work quickly as breakthrough pain's onset is quite rapid.  In addition, many patients may not be able to take other currently available drugs due to difficulty in swallowing, nausea or other gastrointestinal problems.  Our device and array of strengths (100 to 1600 mcg) will allow patients to be treated at their appropriate titrated level.  Finally, we were excited to see that 97% of the patients randomized to the double blind period completed the study, while 92% rolled over to the safety portion."


'/>"/>
SOURCE INSYS Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Clinsys(R) TPS Teams Provide Comprehensive Clinical Development Plans
2. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
3. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
5. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
8. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
9. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
10. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... 11, 2011 Tonight,s "Dan Rather Reports" examines ... of antibiotics. Every year, more than 90,000 Americans ... antibiotic-resistant infections, caused directly by the overuse of ... $35 billion a year.  In tonight,s program, Dan ...
... 2011 WebMD Health Corp. (Nasdaq: WBMD ) ... million aggregate principal amount of 2.50% Convertible Notes due 2018 ... the exercise in full of the initial purchaser,s over-allotment option). ... to Rule 144A under the Securities Act of 1933.   ...
Cached Medicine Technology:Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences? 2Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences? 3Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences? 4WebMD Closes Offering of 2.50% Convertible Notes Due 2018 2
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... 2014) The cause of neuronal death in Parkinson,s ... that neurons may be mistaken for foreign invaders and ... the way autoimmune diseases like type I diabetes, celiac ... study was published April 16, 2014, in Nature ... controversial, idea in Parkinson,s disease; but if true, it ...
(Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
(Date:4/17/2014)... Meaningful long-term survival is possible for selected ... when treated with cytoreductive surgery with Hyperthermic IntraPeritoneal ... by physicians at Wake Forest Baptist Medical Center. ... single-center experience with cytoreductive surgery and HIPEC, said ... of 20 years, worth of patient data shows ...
Breaking Medicine News(10 mins):Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... (MTX) is commonly used to treat rheumatoid arthritis (RA) ... the disease. Despite its widespread use, the understanding of ... joint damage occurs early in the course of RA ... for stable levels of MTX to be reached could ...
... Drug Co-Pays, HOUSTON, Nov. 4 US Oncology ... specialty pharmacy, has,exceeded the $10 million mark in assisting ... of Care Advantage in August 2006., "It was ... to,increase patient access to oral chemotherapies by easing the ...
... defined cell culture media components will feature its productivity maximizing product ... ... CO (PRWEB) November 4, 2008 -- InVitria,s Cellastim (recombinant albumin), which ... will be featured at the 2nd International Cell Engineering Meeting hosted ...
... insecurity, , , TUESDAY, Nov. 4 (HealthDay News) -- Children who ... and undernourished, a new study finds. , The same is ... the impact the most, said study author Dr. Michael Weitzman, ... , "We know that there are long-term consequences of food ...
... 4 Vericept, the leading provider,of data ... is,proud to announce the achievement of a ... in the healthcare industry have selected,Vericept,s DLP ... with,HIPAA, as well as safeguard patient data ...
... Nov. 4 Jennerex, Inc. (San Francisco, CA,and Ottawa, ... Kirn, M.D., President and Chief Executive Officer,will present an ... & Renshaw,Healthcare Conference in New York on November 11, ... at the Palace Hotel, New York., A webcast ...
Cached Medicine News:Health News:Wide variability in rheumatoid arthritis drug suggests alternative dosing should be considered 2Health News:Wide variability in rheumatoid arthritis drug suggests alternative dosing should be considered 3Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 2Health News:OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $10 Million Milestone in Patient Financial Assistance 3Health News:InVitria to Present at WilBio's International Cell Engineering Meeting 2Health News:Smokers' Homes More Likely to House Hungry Kids 2Health News:Smokers' Homes More Likely to House Hungry Kids 3Health News:Vericept Announces 100 Customers in Healthcare Industry for Sensitive Data Protection 2Health News:Jennerex To Present at Rodman & Renshaw 10th Annual Healthcare Conference 2
... True/Flex Upper Extremity Intramedullary Rod System offers ... to conventional methods of rodding and plating. ... at the fracture site and enhanced healing4 ... to be easily inserted into the canal. ...
Interphlex Flexible Stablization Rods offer correction of Hammer Toes with a High level of Flexibility while maintaining correct toe length and shape....
The True/Fix Compression Hip Screw System offers a wide variety of plate and screw sizes available....
... Simple, cost-effective microfiltration for your transfusion ... also brings you an easy and ... of microfiltration for a variety of ... postoperative applications, autologous or homologous transfusions, ...
Medicine Products: